Dr Reddy's Laboratories Free Cash Flow 2011-2025 | RDY
Dr Reddy's Laboratories annual/quarterly free cash flow history and growth rate from 2011 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Dr Reddy's Laboratories free cash flow for the quarter ending September 30, 2025 was 206.00, a year-over-year.
- Dr Reddy's Laboratories free cash flow for the twelve months ending September 30, 2025 was , a year-over-year.
- Dr Reddy's Laboratories annual free cash flow for 2025 was $0.229B, a 36.57% decline from 2024.
- Dr Reddy's Laboratories annual free cash flow for 2024 was $0.361B, a 37.65% decline from 2023.
- Dr Reddy's Laboratories annual free cash flow for 2023 was $0.579B, a 218.13% increase from 2022.
| Dr Reddy's Laboratories Annual Free Cash Flow | |
|---|---|
| 2025 | 229.00 |
| 2024 | 361.00 |
| 2023 | 579.00 |
| 2022 | 182.00 |
| 2021 | 356.00 |
| 2020 | 334.00 |
| 2019 | 332.00 |
| 2018 | 136.00 |
| 2017 | 144.00 |
| 2016 | 443.00 |
| 2015 | 255.00 |
| 2014 | 157.00 |
| 2013 | 123.00 |
| 2012 | 183.00 |
| 2011 | -16.00 |
| Dr Reddy's Laboratories Quarterly Free Cash Flow | |
|---|---|
| 2025-09-30 | 206.00 |
| 2025-06-30 | 91.00 |
| 2025-03-31 | 229.00 |
| 2024-12-31 | 60.00 |
| 2024-09-30 | 66.00 |
| 2024-06-30 | 43.00 |
| 2024-03-31 | 361.00 |
| 2023-12-31 | 286.00 |
| 2023-09-30 | 269.00 |
| 2023-06-30 | 93.00 |
| 2023-03-31 | 579.00 |
| 2022-12-31 | 369.00 |
| 2022-09-30 | 126.00 |
| 2022-06-30 | 44.00 |
| 2022-03-31 | 182.00 |
| 2021-12-31 | 111.00 |
| 2021-09-30 | -67.08 |
| 2021-06-30 | -88.00 |
| 2021-03-31 | 356.00 |
| 2020-12-31 | 242.00 |
| 2020-09-30 | 220.00 |
| 2020-06-30 | 124.00 |
| 2020-03-31 | 334.00 |
| 2019-12-31 | 340.00 |
| 2019-09-30 | 256.00 |
| 2019-06-30 | 133.00 |
| 2019-03-31 | 332.00 |
| 2018-12-31 | 271.00 |
| 2018-09-30 | 45.00 |
| 2018-06-30 | -102.00 |
| 2018-03-31 | 136.00 |
| 2017-12-31 | 71.00 |
| 2017-09-30 | -12.00 |
| 2017-06-30 | -74.00 |
| 2017-03-31 | 144.00 |
| 2016-12-31 | 56.00 |
| 2016-09-30 | 22.00 |
| 2016-06-30 | 27.00 |
| 2016-03-31 | 443.00 |
| 2015-12-31 | 352.00 |
| 2015-09-30 | 220.00 |
| 2015-06-30 | 95.00 |
| 2015-03-31 | 255.00 |
| 2014-12-31 | 125.00 |
| 2014-09-30 | 79.00 |
| 2014-06-30 | 42.00 |
| 2014-03-31 | 157.00 |
| 2013-12-31 | 56.00 |
| 2013-09-30 | -5.00 |
| 2013-06-30 | 42.00 |
| 2013-03-31 | 123.00 |
| 2012-12-31 | 105.82 |
| 2012-09-30 | 69.00 |
| 2012-06-30 | 36.00 |
| 2012-03-31 | 183.00 |
| 2011-12-31 | 83.00 |
| 2011-09-30 | 14.00 |
| 2011-06-30 | 24.00 |
| 2011-03-31 | -16.00 |
| 2010-12-31 | 11.49 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.580B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $29.293B | 9.90 |
| BridgeBio Pharma (BBIO) | United States | $12.538B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.548B | 20.86 |
| Bausch Health Cos (BHC) | Canada | $2.455B | 1.74 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.212B | 8.73 |
| Taysha Gene Therapies (TSHA) | United States | $1.098B | 0.00 |
| Personalis (PSNL) | United States | $0.675B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.273B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.099B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.017B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |